Market closedNon-fractional

Guardant Health/GH

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Ticker

GH

Sector

Healthcare

Trading on

NASDAQ

Industry

Health Care Providers and Services

Headquarters

Palo Alto, United States

Employees

1,774

Guardant Health Metrics

BasicAdvanced
$3.5B
Market cap
-
P/E ratio
-$3.95
EPS
0.92
Beta
-
Dividend rate
$3.5B
0.92
5.948
5.062
1,932.369
1,973.31
-172.49%
-17.29%
-3,883.89%
5.58
51.65
62.2
-11.21
25.21%
-39.21%
26.55%
5.25%

What the Analysts think about Guardant Health

Analyst Ratings

Majority rating from 22 analysts.
Buy

Guardant Health Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-68.23% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$168M
8.65%
Net income
-$115M
-38.56%
Profit margin
-68.23%
-43.44%

Guardant Health Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 10.35%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.67
-$0.73
-$1.58
-$0.94
-
Expected
-$1.17
-$0.94
-$0.86
-$0.85
-$0.76
Surprise
-42.65%
-22.67%
82.79%
10.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Guardant Health stock?

Guardant Health (GH) has a market cap of $3.5B as of July 04, 2024.

What is the P/E ratio for Guardant Health stock?

The price to earnings (P/E) ratio for Guardant Health (GH) stock is 0 as of July 04, 2024.

Does Guardant Health stock pay dividends?

No, Guardant Health (GH) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Guardant Health dividend payment date?

Guardant Health (GH) stock does not pay dividends to its shareholders.

What is the beta indicator for Guardant Health?

Guardant Health (GH) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Guardant Health stock

Buy or sell Guardant Health stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing